Roles > HIV-1 maturation inhibitor
Page last updated: 2024-08-05 15:43:15
HIV-1 maturation inhibitor
A compound that blocks the processing of the Gag precursor protein in HIV-1 by the viral protease enzyme, leading to the formation of noninfectious, immature virus particles that are incapable of infecting other cells.
ChEBI ID: 71168
Members (1)
| Member | Definition | Class |
|---|
| bevirimat | A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems. | bevirimat |
Research
Studies (106)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.89) | 18.2507 |
| 2000's | 49 (46.23) | 29.6817 |
| 2010's | 43 (40.57) | 24.3611 |
| 2020's | 12 (11.32) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|
| Trials | 5 (4.55%) | 5.53% |
| Reviews | 13 (11.82%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 92 (83.64%) | 84.16% |
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | IC50 | 0.5520 | 1 | 1 |
| Protease | Human immunodeficiency virus 1 | IC50 | 171.0000 | 1 | 1 |
Activation Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | EC50 | 0.4369 | 5 | 5 |